Product Images Plavix

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Plavix NDC 54868-4070 by Physicians Total Care, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PRINCIPAL DISPLAY PANEL - 75 mg label - 4070

PRINCIPAL DISPLAY PANEL - 75 mg label - 4070

Chemical Structure - plavix 01

Chemical Structure - plavix 01

Figure - plavix 02

Figure - plavix 02

Figure - plavix 03

Figure - plavix 03

This is a graphical representation of the cumulative event rate for cardiovascular death, myocardial infarction, and stroke over the course of 12 months of follow-up for patients taking either a placebo or Plavix with aspirin. The graph shows that Plavix with aspirin resulted in a significantly lower cumulative event rate compared to placebo with aspirin.*

Figure - plavix 04

Figure - plavix 04

This is a table of characteristics and outcomes for patients on Plavix versus placebo with respect to different diagnoses, demographic factors, and concomitant medications. The table displays the percent events for each category as well as the Hazard Ratio (95% CI).*

Figure - plavix 05

Figure - plavix 05

The text appears to be a comparison of the mortality rates of Placebo and Clopidogrel (a medication used to prevent blood clots) in patients. The data shows that out of 1845 patients who had taken Placebo, 8.1% had died while out of 1726 patients who had taken Clopidogrel, 7.5% had died. The text also includes mention of "proportional risk before reduction" and a "p-value of 0.03". The timeline of the study is also noted, which involved a total of 28 days.*

Figure - plavix 06

Figure - plavix 06

This appears to be a statistical report comparing Placebo and Clopidogrel in terms of re-infarction reduction after discharge, with data presented for up to 28 days from randomization. Both groups had a significant rate of events, with Clopidogrel appearing to have a slightly lower rate than Placebo (9.2% vs 10.1%). The report also states a proportional risk reduction of death and re-infarction (p=0.002) for Clopidogrel. There are some unclear symbols and formatting issues in the text provided, but this is the best interpretation based on the given material.*

Figure - plavix 07

Figure - plavix 07

Figure - plavix 08

Figure - plavix 08

This is a statistical table with information related to the effect of clopidogrel on different events and conditions. It includes the categorization, number of participants in each group, odds ratios, confidence intervals, and heterogeneity tests. The data suggests that clopidogrel is better than placebo in reducing proportional reduction in total events, with a p-value of 0.002. The table also includes information about Killip class, previous MI, and infarct location.*

Figure - plavix 09

Figure - plavix 09

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.